Five years of clinical experience with metronomic chemotherapy: Achievements and perspectives

Onkologie

Volumn 30, Issue 12, 2007, Pages 606-608

  Emmenegger, Urban ^a   Kerbel, Robert S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GLITAZONE DERIVATIVE; LETROZOLE; METHOTREXATE; MINOCYCLINE; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; UFT;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD FLOW VELOCITY; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DRUG SAFETY; EDITORIAL; EXPERIENCE; FATIGUE; HUMAN; KIDNEY CANCER; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; METASTASIS; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHUMAN; OVARY CANCER; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; TRANSAMINITIS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; FORECASTING; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME;

EID: 37049031698     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111479     Document Type: Editorial

References (29)

1. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 2005;438(7070):967-74.
2. Kerbel RS: Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006;312(5777):1171-5.
3. Miller KD, Sweeney CJ, Sledge GW, Jr.: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19(4):1195-206.
4. Kerbel RS, Viloria-Petit A, Klement G, Rak J: 'Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000;36(10):1248-57.
5. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60(7):1878-86.
6. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous lowdose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105(8):R15-24.
7. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4(6):423-36.
8. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105(8):1045-7.
9. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B: Metronomic cyclophosphamide regimen selectively depletes CD4(+)CD25 (+) regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56(5):641-648.
10. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13(1):73-80.
11. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nole F, Viale G, Goldhirsch A: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006;17(2):232-8.
12. Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A: Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006;24(22):3623-8.
13. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R: Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003;98(8):1643-8.
14. Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H: Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study. J Urol 2007;177(6):2136-2140.
15. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz H-J, Oza AM: Phase II clinical trial of bevacizumab and low dose metronomic oral cyclophosphamide in recurrent ovarian cancer. A study of the California, Chicago and Princess Margaret Hospital Phase II Consortia. J Clin Oncol 2007 in press.
16. Gille J, Spieth K, Kaufmann R: Metronomic lowdose chemotherapy as antiangiogenic therapeutic strategy for cancer. J Dtsch Dermatol Ges 2005;3(1):26-32.
17. Krzyzanowska MK, Tannock IF, Lockwood G, Knox J, Moore M, Bjarnason GA: A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol 2007;60(1):135-41.
18. Burstein HJ, Spigel D, Kindsvogel K, Parker LM, Bunnel CA, Partridge AH, Come SE, Ryan PD, Gelman R, Winer EP: Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. San Antonio Breast Cancer Symposium, Breast Cancer Res Treat. 2005;95(suppl 1):S6, abstr # 4.
19. Rocca A, Dellapasqua S, Pietri E, Dettori M, D'Alessandro C, Ghisini R, Colombo A, Goldhirsch A, Colleoni M: Metronomic chemotherapy with capecitabine and oral cyclophosphamide in combination with bevacizumab in metastatic breast cancer (mbc): Evidence of activity of an antianigogenic treatment. ASCO Annual Meeting 2007, abstr # 11501.
20. Steinbild S, Arends J, Medinger M, Haering B, Frost A, Drevs J, Unger C, Strecker R, Hennig J, Mross K: Metronomic antiangiogenic therapy with capecitabine and celecoxib (CC) in advanced tumor patients - results of a phase II study. Onkologie 2007;30: DOI: 10.1159/000110580.
21. Loven D, Be'ery E, Yerushalmi R, Koren C, Sulkes A, Lavi I, Shaked Y, Fenig E: Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. Acta Oncol 2007;July 5:1-6 [Epub ahead of print].
22. Rak J, Yu JL, Kerbel RS, Coomber BL: What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res 2002;62(7):1931-4.
23. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS: Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66(7):3386-91.
24. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, Ohta M; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350(17):1713-21.
25. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F: Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108(2):452-9.
26. Takahashi Y, Mai M, Sawabu N, Nishioka K: A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. Pancreas 2005;30(3):206-10.
27. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M: High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006;12(17):5190-8.
28. Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ: Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 2006;12(10):3092-8.
29. Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, Peruzzotti G, Goldhirsch A, Pietri E, Colleoni M: Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006;6:225.